We are pleased to feature our latest open-access review published in Experimental & Molecular Medicine, titled “The Functional Imperative in High-Grade Glioma.” Despite more than 300 clinical trials evaluating targeted and precision therapies, outcomes for patients with high-grade glioma have seen limited improvement. This review examines why predominantly marker-driven, static precision oncology approaches have underperformed and revisits key biological and therapeutic lessons from historical and contemporary treatment strategies. The article advances Functional Precision Oncology (FPO) as a complementary paradigm, leveraging living, patient-derived glioma models to dynamically assess drug sensitivity and resistance in a patient-specific manner. By integrating functional testing with molecular profiling, FPO offers a practical route toward more actionable and personalized clinical decision-making for patients with glioma.
Read the full open-access article: https://www.nature.com/articles/s12276-025-01614-x
Goh, L.S.H., Thng, D.K.H., Ang, Y.L.E. et al. The functional imperative in high-grade glioma. Exp Mol Med (2026). https://doi.org/10.1038/s12276-025-01614-x